Quince Therapeutics (QNCX) Stock Price, News & Analysis

Company Overview

Quince Therapeutics, Inc. (NASDAQ:QNCX) is a clinical-stage biotechnology company developing therapies for rare and debilitating diseases. The company focuses on precision medicines designed to address underlying disease mechanisms and unmet medical needs in patient populations that may have limited treatment options.

Quince’s pipeline includes efzofitimod, an investigational immunomodulator being developed for pulmonary sarcoidosis, a rare inflammatory disease that can affect lung function. The company is also advancing an erythrocyte-based drug-delivery platform, known as EryDex, which is designed to use a patient’s red blood cells to deliver therapeutic compounds. Its lead EryDex-based program is being evaluated for ataxia-telangiectasia, a rare inherited neurodegenerative disorder.

The company was formerly known as Cortexyme, Inc. and adopted the Quince Therapeutics name as it shifted its strategic focus toward rare-disease therapeutics. Its research and clinical programs are intended for patients in the United States and international markets, subject to regulatory approval. Quince is headquartered in California and conducts development activities through collaborations and clinical studies in multiple regions.

Key Stats

• Today's Range: $31.73 to $31.73
• 50-Day Range: $26.72 to $34.57
• 52-Week Range: $15.10 to $909.98
• Volume: N/A
• Average Volume: 31,090 shs
• Market Capitalization: $32.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $189.88
• Consensus Rating: Moderate Buy

Quince Therapeutics Stock Analysis - MarketRank™

Quince Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 413th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Quince Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 2 strong buy ratings, 7 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Quince Therapeutics has a consensus price target of $189.88, representing about 498.4% upside from its current price of $31.73.

Amount of Analyst Coverage

Quince Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quince Therapeutics are expected to grow in the coming year, from ($8.39) to ($3.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.24% of the float of Quince Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Quince Therapeutics has a short interest ratio ("days to cover") of 2.67, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quince Therapeutics has recently increased by 19.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quince Therapeutics does not currently pay a dividend.

Dividend Growth

Quince Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.40

News Sentiment

Quince Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for QNCX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quince Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.60% of the stock of Quince Therapeutics is held by insiders.

Percentage Held by Institutions

30.75% of the stock of Quince Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QNCX
• Previous Symbol: NASDAQ:CRTX
• CIK: 1662774
• Web: www.quincetx.com
• Phone: (415) 910-5717
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Quince Therapeutics: $189.88
• High Price Target: $1,000.00
• Low Price Target: $68.00
• Potential Upside/Downside: +498.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($156.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -133.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.52
• Quick Ratio: 14.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($128.18) per share
• Price / Book: -0.25

Miscellaneous

• Outstanding Shares: 1,017,000
• Free Float: 960,000
• Market Cap: $32.27 million
• Optionable: Optionable
• Beta: 1.33